Vasomotor Menopausal Symptoms (VMS) Treatment Global Market Report 2025

Vasomotor Menopausal Symptoms (VMS) Treatment Global Market Report 2024

Vasomotor Menopausal Symptoms (VMS) Treatment Global Market Report 2025 – By Drug Class (Antidepressants, Fluoxetine, Paroxetine, Sertraline, Hormone Therapy, Anticonvulsant, Phenytoin, Phenobarbital, Other Drug Classes), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels), By End-User (Hospitals, Specialty Clinics, Homecare, Other End-Users) – Market Size, Trends, And Global Forecast 2025-2034

Name: Vasomotor Menopausal Symptoms (VMS) Treatment Global Market Report 2025
Creator: The Business Research Company
License: https://www.thebusinessresearchcompany.com/privacy-policy

Vasomotor Menopausal Symptoms (VMS) Treatment Global Market Report 2025

Report Price : $4490.00 | Pages : 175 | Published : January 2025 | Delivery Time: 2-3 business days | Format : pdf

Purchase Options

Request a Sample

Request For Discount

Customise Your Report

Item added to cart!

Request For Proposal

Request For Regional Data

FAQs

Need assistance or more information before the purchase?

Enquire Before Buying

Vasomotor Menopausal Symptoms (VMS) Treatment Global Market Report 2025

Proud Members Of

Vasomotor Menopausal Symptoms (VMS) Treatment Market Definition

Vasomotor menopausal symptoms (VMS) treatment refers to the medical interventions and therapies used to alleviate or manage the various symptoms associated with menopause. Women experience the symptoms of VMS during menopause, which include hot flashes and night sweats. The treatment works by balancing hormone levels in the body and altering neurotransmitters in the brain.

The main types of drugs in vasomotor menopausal symptoms (VMS) treatment are antidepressants, fluoxetine, paroxetine, sertraline, hormone therapy, anticonvulsants, phenytoin, phenobarbital and others. Antidepressants refer to a class of medications primarily used to treat depression and certain other mental health disorders. They are distributed in several ways, such as in hospital pharmacies, online pharmacies, retail pharmacies and others for various end-users such as hospitals, specialty clinics, homecare and others.

Vasomotor Menopausal Symptoms (VMS) Treatment Market Segmentation

The vasomotor menopausal symptoms (VMS) treatment market covered in this report is segmented –

1) By Drug Class: Antidepressants, Fluoxetine, Paroxetine, Sertraline, Hormone Therapy, Anticonvulsant, Phenytoin, Phenobarbital, Other Drug Classes

2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

3) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-Users

Subsegments:

1) By Antidepressants: SSRIs (Selective Serotonin Reuptake Inhibitors), SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors), TCAs (Tricyclic Antidepressants), MAOIs (Monoamine Oxidase Inhibitors), Atypical Antidepressants

2) By Fluoxetine: Depression, Obsessive-Compulsive Disorder (OCD), Panic Disorder, Generalized Anxiety Disorder (GAD), Post-Traumatic Stress Disorder (PTSD), Social Anxiety Disorder, Premenstrual Dysphoric Disorder (PMDD)

3) By Paroxetine: Depression, Obsessive-Compulsive Disorder (OCD), Panic Disorder, Generalized Anxiety Disorder (GAD), Post-Traumatic Stress Disorder (PTSD), Social Anxiety Disorder, Premenstrual Dysphoric Disorder (PMDD)

4) Sertraline: Depression, Obsessive-Compulsive Disorder (OCD), Panic Disorder, Post-Traumatic Stress Disorder (PTSD), Social Anxiety Disorder, Premenstrual Dysphoric Disorder (PMDD)

5) Hormone Therapy: Estrogen Replacement Therapy (ERT), Progestin Therapy, Combined Hormonal Therapy (CHT), Testosterone Replacement Therapy (TRT)

6) Anticonvulsant: Hydantoins, Barbiturates, Benzodiazepines, Valproates, Succinimides, Carboxylic Acid Derivatives

7) Phenytoin: Hydantoins

8) Phenobarbital: Barbiturates

9) Other Drug Classes: Antibiotics, Analgesics, Antidiabetics, Antihypertensives, Anticoagulants, Immunosuppressants, Antipsychotics, Antihistamines

Vasomotor Menopausal Symptoms (VMS) Treatment Market Size and growth rate 2025 to 2029: Graph

Vasomotor Menopausal Symptoms (VMS) Treatment Market Size 2025 And Growth Rate

The vasomotor menopausal symptoms (VMS) treatment market size has grown strongly in recent years. It will grow from $17.86 billion in 2024 to $19.19 billion in 2025 at a compound annual growth rate (CAGR) of 7.5%. The growth in the historic period can be attributed to hormone replacement therapy (hrt), menopause awareness, pharmaceutical developments, consumer demand.

Vasomotor Menopausal Symptoms (VMS) Treatment Market Growth Forecast

The vasomotor menopausal symptoms (VMS) treatment market size is expected to see strong growth in the next few years. It will grow to $24.81 billion in 2029 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to personalized medicine, non-hormonal innovations, nutritional and dietary interventions, telemedicine and digital health. Major trends in the forecast period include natural and alternative approaches, botanical and herbal remedies, menopause support groups, cognitive behavioral therapy (cbt).

Book your 30 minutes free consultation with our research experts

Vasomotor Menopausal Symptoms (VMS) Treatment Market Driver: Menopausal Population Growth Fuels Expansion Of Vasomotor Menopausal Symptoms Treatment Market

The increase in the menopause population is expected to propel the growth of the vasomotor menopausal symptom’s treatment market going forward. Menopause is a natural biological process that marks the end of a woman's reproductive years. It is a significant life stage that typically occurs in women between the ages of 45 and 55, with the average age being around 51. The rising number of menopausal women, which demands treatment for hot flashes and vaginal dryness globally, is one of the primary factors pushing the growth of vasomotor menopausal symptoms (VMS) treatment. For instance, in November 2022, according to the Cuyuna Regional Medical Center, a US-based organization, estimated that by 2025, 1.1 billion women will be menopausal due to women living longer. Moreover, the population of menopausal will be increased by 1.6% annually until 2060. Therefore, the increase in the menopause population is driving the growth of the vasomotor menopausal symptom’s treatment market.

Vasomotor Menopausal Symptoms (VMS) Treatment Market Driver: Government Women's Health Initiatives Boost Vasomotor Menopausal Symptom Treatment Market

The government's initiatives for women's health in menopause are expected to propel the growth of the vasomotor menopausal symptom’s treatment market going forward. Government initiatives for menopausal health encompass funding for innovative studies on menopausal transition, illness prevention, and research related pharmacological, clinical, and epidemiological aspects. These efforts are part of broader women's health initiatives that address diverse concerns. For instance, in January 2023, according to the Government of New South Wales, an Australia-based government agency, the government initiated $40.3 million over four years (2022-2023 to 2025-2026) to build up to 16 new programs for women facing severe menopausal symptoms. Therefore, the government's initiatives for women's health in menopause are driving the growth of the vasomotor menopausal symptoms’ treatment market.

Global Vasomotor Menopausal Symptoms (VMS) Treatment Market Major Players

Major companies operating in the vasomotor menopausal symptoms (VMS) treatment market are Pfizer Inc., Abbvie Inc., Novartis AG, Ausio Pharmaceuticals LLC, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Kyowa Kirin Co. Ltd., Dr. Reddy's Laboratories Ltd., Alembic Pharmaceuticals Limited Inc., Apotex Inc., Hikma Pharmaceutical PLC, Endo Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Mundipharma International Ltd., Lupin Limited, Glenmark Pharmaceuticals Ltd., Hisamitsu Pharmaceutical Co. Inc., Zhejiang Huahai Pharmaceutical Co. Ltd., Emcure Pharmaceuticals Limited, Wockhardt Pvt. Ltd., QuatRx Pharmaceuticals Company, Bionovo Inc., Mithra Pharmaceuticals SA, EndoCeutics Inc., Zydus Group, Edgemont Pharmaceuticals LLC, MenoGeniX Inc., Agile Therapeutics Inc.

Global Vasomotor Menopausal Symptoms (VMS) Treatment Market Trend: Increasing The Emphasis On Drug Approvals To Provide Better Treatment Options

Major companies operating in the vasomotor menopausal symptoms treatment market are developing products such as Veozah and getting approvals to provide new treatment options and meet unmet medical needs for patients. The approval of new drugs for menopause provides improved efficacy and safety compared to existing treatments. For instance, in May 2023, Astellas Pharma Inc, a Japan-based pharmaceutical company, received approval for Veozah (fezolinetant) 45 mg once daily from the Food and Drug Administration (FDA), a US-based federal agency for the treatment of menopausal vasomotor symptoms (VMS), which range from mild to severe. It is the first nonhormonal neurokinin 3 (NK3) receptor antagonist to be authorized for treating menopausal-related VMS. It is a hormone-free option that blocks a pathway in the brain that helps regulate these symptoms. It provides an alternative treatment option for women experiencing these symptoms, particularly those who cannot or prefer not to use hormone therapy. The approval of Veozah highlights its potential as a new drug for managing menopausal symptoms.

Vasomotor Menopausal Symptoms (VMS) Treatment Market Merger And Acquisition: Amyris Inc. Expands Women's Health Portfolio With Acquisition Of Menolabs Llc

In March 2022, Amyris Inc., a US-based biotechnology company, acquired MenoLabs LLC for $35.4 million. With this acquisition, Amyris aims to expand its women's health market presence, gain access to new technologies and capabilities and acquire a loyal customer base. MenoLabs LLC is a US-based women's health and technology company that develops dietary supplements to treat women's menopause symptoms.

Regional Outlook For The Global Vasomotor Menopausal Symptoms (VMS) Treatment Market

North America was the largest region in the vasomotor menopausal symptoms (VMS) treatment market in 2024. The regions covered in vasomotor menopausal symptoms (VMS) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the vasomotor menopausal symptoms (VMS) treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Vasomotor Menopausal Symptoms (VMS) Treatment Market?

The vasomotor menopausal symptoms (VMS) treatment market consists of revenues earned by entities by providing services such as cognitive-behavioral therapy, acupuncture, lifestyle modifications, herbal and vitamin supplements and complementary and alternative therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The vasomotor menopausal symptoms (VMS) treatment market also includes sales of natural supplements, cooling products, vaginal estrogen products, stress-reduction products, sleep aids and dietary supplements. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Vasomotor Menopausal Symptoms (VMS) Treatment Industry?

The vasomotor menopausal symptoms (VMS) treatment market research report is one of a series of new reports from The Business Research Company that provides vasomotor menopausal symptoms (VMS) treatment market statistics, including vasomotor menopausal symptoms (VMS) treatment industry global market size, regional shares, competitors with a vasomotor menopausal symptoms (VMS) treatment market share, detailed vasomotor menopausal symptoms (VMS) treatment market segments, market trends and opportunities and any further data you may need to thrive in the vasomotor menopausal symptoms (VMS) treatment industry. This vasomotor menopausal symptoms (VMS) treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Vasomotor Menopausal Symptoms (VMS) Treatment Market Report Forecast Analysis

Report Attribute	Details
Market Size Value In 2025	$19.19 billion
Revenue Forecast In 2034	$24.81 billion
Growth Rate	CAGR of 6.6% from 2025 to 2034
Base Year For Estimation	2024
Actual Estimates/Historical Data	2019-2024
Forecast Period	2025 - 2029 - 2034
Market Representation	Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered	1) By Drug Class: Antidepressants, Fluoxetine, Paroxetine, Sertraline, Hormone Therapy, Anticonvulsant, Phenytoin, Phenobarbital, Other Drug Classes 2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels 3) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-Users Subsegments: 1) By Antidepressants: SSRIs (Selective Serotonin Reuptake Inhibitors), SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors), TCAs (Tricyclic Antidepressants), MAOIs (Monoamine Oxidase Inhibitors), Atypical Antidepressants 2) By Fluoxetine: Depression, Obsessive-Compulsive Disorder (OCD), Panic Disorder, Generalized Anxiety Disorder (GAD), Post-Traumatic Stress Disorder (PTSD), Social Anxiety Disorder, Premenstrual Dysphoric Disorder (PMDD) 3) By Paroxetine: Depression, Obsessive-Compulsive Disorder (OCD), Panic Disorder, Generalized Anxiety Disorder (GAD), Post-Traumatic Stress Disorder (PTSD), Social Anxiety Disorder, Premenstrual Dysphoric Disorder (PMDD) 4) Sertraline: Depression, Obsessive-Compulsive Disorder (OCD), Panic Disorder, Post-Traumatic Stress Disorder (PTSD), Social Anxiety Disorder, Premenstrual Dysphoric Disorder (PMDD) 5) Hormone Therapy: Estrogen Replacement Therapy (ERT), Progestin Therapy, Combined Hormonal Therapy (CHT), Testosterone Replacement Therapy (TRT) 6) Anticonvulsant: Hydantoins, Barbiturates, Benzodiazepines, Valproates, Succinimides, Carboxylic Acid Derivatives 7) Phenytoin: Hydantoins 8) Phenobarbital: Barbiturates 9) Other Drug Classes: Antibiotics, Analgesics, Antidiabetics, Antihypertensives, Anticoagulants, Immunosuppressants, Antipsychotics, Antihistamines
Regional Scope	Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope	The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled	Pfizer Inc., Abbvie Inc., Novartis AG, Ausio Pharmaceuticals LLC, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Kyowa Kirin Co. Ltd., Dr. Reddy's Laboratories Ltd., Alembic Pharmaceuticals Limited Inc., Apotex Inc., Hikma Pharmaceutical plc, Endo Pharmaceuticals plc, Amneal Pharmaceuticals LLC, Mundipharma International Ltd., Lupin Limited, Glenmark Pharmaceuticals Ltd., Hisamitsu Pharmaceutical Co. Inc., Zhejiang Huahai Pharmaceutical Co. Ltd., Emcure Pharmaceuticals Limited, Wockhardt Pvt. Ltd., QuatRx Pharmaceuticals Company, Bionovo Inc., Mithra Pharmaceuticals SA, EndoCeutics Inc., Zydus Group, Edgemont Pharmaceuticals LLC, MenoGeniX Inc., Agile Therapeutics Inc.
Customization Scope	Request for Sample
Pricing And Purchase Options	Explore Purchase Options

1. Executive Summary

2. Vasomotor Menopausal Symptoms (VMS) Treatment Market Characteristics

3. Vasomotor Menopausal Symptoms (VMS) Treatment Market Trends And Strategies

4. Vasomotor Menopausal Symptoms (VMS) Treatment Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Vasomotor Menopausal Symptoms (VMS) Treatment Growth Analysis And Strategic Analysis Framework

5.1. Global Vasomotor Menopausal Symptoms (VMS) Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market Growth Rate Analysis

5.4. Global Vasomotor Menopausal Symptoms (VMS) Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global Vasomotor Menopausal Symptoms (VMS) Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global Vasomotor Menopausal Symptoms (VMS) Treatment Total Addressable Market (TAM)

6. Vasomotor Menopausal Symptoms (VMS) Treatment Market Segmentation

6.1. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Antidepressants

Fluoxetine

Paroxetine

Sertraline

Hormone Therapy

Anticonvulsant

Phenytoin

Phenobarbital

Other Drug Classes

6.2. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy

Other Distribution Channels

6.3. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospitals

Specialty Clinics

Homecare

Other End-Users

6.4. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Antidepressants, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

SSRIs (Selective Serotonin Reuptake Inhibitors)

SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors)

TCAs (Tricyclic Antidepressants)

MAOIs (Monoamine Oxidase Inhibitors)

Atypical Antidepressants

6.5. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Fluoxetine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Depression

Obsessive-Compulsive Disorder (OCD)

Panic Disorder

Generalized Anxiety Disorder (GAD)

Post-Traumatic Stress Disorder (PTSD)

Social Anxiety Disorder

Premenstrual Dysphoric Disorder (PMDD)

6.6. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Paroxetine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Depression

Obsessive-Compulsive Disorder (OCD)

Panic Disorder

Generalized Anxiety Disorder (GAD)

Post-Traumatic Stress Disorder (PTSD)

Social Anxiety Disorder

Premenstrual Dysphoric Disorder (PMDD)

6.7. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Sertraline, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Depression

Obsessive-Compulsive Disorder (OCD)

Panic Disorder

Post-Traumatic Stress Disorder (PTSD)

Social Anxiety Disorder

Premenstrual Dysphoric Disorder (PMDD)

6.8. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Hormone Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Estrogen Replacement Therapy (ERT)

Progestin Therapy

Combined Hormonal Therapy (CHT)

Testosterone Replacement Therapy (TRT)

6.9. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Anticonvulsant, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hydantoins

Barbiturates

Benzodiazepines

Valproates

Succinimides

Carboxylic Acid Derivatives

6.10. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Phenytoin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hydantoins

6.11. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Phenobarbital, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Barbiturates

6.12. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Antibiotics

Analgesics

Antidiabetics

Antihypertensives

Anticoagulants

Immunosuppressants

Antipsychotics

Antihistamines'

7. Vasomotor Menopausal Symptoms (VMS) Treatment Market Regional And Country Analysis

7.1. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Vasomotor Menopausal Symptoms (VMS) Treatment Market

8.1. Asia-Pacific Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Vasomotor Menopausal Symptoms (VMS) Treatment Market

9.1. China Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview

9.2. China Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Vasomotor Menopausal Symptoms (VMS) Treatment Market

10.1. India Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Vasomotor Menopausal Symptoms (VMS) Treatment Market

11.1. Japan Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview

11.2. Japan Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Vasomotor Menopausal Symptoms (VMS) Treatment Market

12.1. Australia Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Vasomotor Menopausal Symptoms (VMS) Treatment Market

13.1. Indonesia Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Vasomotor Menopausal Symptoms (VMS) Treatment Market

14.1. South Korea Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview

14.2. South Korea Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Vasomotor Menopausal Symptoms (VMS) Treatment Market

15.1. Western Europe Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview

15.2. Western Europe Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Vasomotor Menopausal Symptoms (VMS) Treatment Market

16.1. UK Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Vasomotor Menopausal Symptoms (VMS) Treatment Market

17.1. Germany Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Vasomotor Menopausal Symptoms (VMS) Treatment Market

18.1. France Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Vasomotor Menopausal Symptoms (VMS) Treatment Market

19.1. Italy Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Vasomotor Menopausal Symptoms (VMS) Treatment Market

20.1. Spain Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Vasomotor Menopausal Symptoms (VMS) Treatment Market

21.1. Eastern Europe Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview

21.2. Eastern Europe Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Vasomotor Menopausal Symptoms (VMS) Treatment Market

22.1. Russia Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Vasomotor Menopausal Symptoms (VMS) Treatment Market

23.1. North America Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview

23.2. North America Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Vasomotor Menopausal Symptoms (VMS) Treatment Market

24.1. USA Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview

24.2. USA Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Vasomotor Menopausal Symptoms (VMS) Treatment Market

25.1. Canada Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview

25.2. Canada Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Vasomotor Menopausal Symptoms (VMS) Treatment Market

26.1. South America Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview

26.2. South America Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Vasomotor Menopausal Symptoms (VMS) Treatment Market

27.1. Brazil Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Vasomotor Menopausal Symptoms (VMS) Treatment Market

28.1. Middle East Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview

28.2. Middle East Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Vasomotor Menopausal Symptoms (VMS) Treatment Market

29.1. Africa Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview

29.2. Africa Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Vasomotor Menopausal Symptoms (VMS) Treatment Market Competitive Landscape And Company Profiles

30.1. Vasomotor Menopausal Symptoms (VMS) Treatment Market Competitive Landscape

30.2. Vasomotor Menopausal Symptoms (VMS) Treatment Market Company Profiles

30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.2. Abbvie Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

30.2.4. Ausio Pharmaceuticals LLC Overview, Products and Services, Strategy and Financial Analysis

30.2.5. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis

31. Vasomotor Menopausal Symptoms (VMS) Treatment Market Other Major And Innovative Companies

31.1. Mylan N.V.

31.2. Sun Pharmaceutical Industries Ltd.

31.3. Aurobindo Pharma Limited

31.4. Kyowa Kirin Co. Ltd.

31.5. Dr. Reddy's Laboratories Ltd.

31.6. Alembic Pharmaceuticals Limited Inc.

31.7. Apotex Inc.

31.8. Hikma Pharmaceutical plc

31.9. Endo Pharmaceuticals plc

31.10. Amneal Pharmaceuticals LLC

31.11. Mundipharma International Ltd.

31.12. Lupin Limited

31.13. Glenmark Pharmaceuticals Ltd.

31.14. Hisamitsu Pharmaceutical Co. Inc.

31.15. Zhejiang Huahai Pharmaceutical Co. Ltd.

32. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Vasomotor Menopausal Symptoms (VMS) Treatment Market

34. Recent Developments In The Vasomotor Menopausal Symptoms (VMS) Treatment Market

35. Vasomotor Menopausal Symptoms (VMS) Treatment Market High Potential Countries, Segments and Strategies

35.1 Vasomotor Menopausal Symptoms (VMS) Treatment Market In 2029 - Countries Offering Most New Opportunities

35.2 Vasomotor Menopausal Symptoms (VMS) Treatment Market In 2029 - Segments Offering Most New Opportunities

35.3 Vasomotor Menopausal Symptoms (VMS) Treatment Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

Table 1: Global Historic Market Growth, 2019-2024, $ Billion

Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Table 3: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 4: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 5: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 6: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Antidepressants, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 7: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Fluoxetine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 8: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Paroxetine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 9: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Sertraline, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 10: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Hormone Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 11: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Anticonvulsant, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 12: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Phenytoin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 13: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Phenobarbital, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 14: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 15: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 16: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 17: Asia-Pacific, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 18: Asia-Pacific, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 19: Asia-Pacific, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 20: China, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 21: China, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 22: China, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 23: India, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 24: India, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 25: India, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 26: Japan, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 27: Japan, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 28: Japan, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 29: Australia, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 30: Australia, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 31: Australia, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 32: Indonesia, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 33: Indonesia, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 34: Indonesia, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 35: South Korea, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 36: South Korea, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 37: South Korea, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 38: Western Europe, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 39: Western Europe, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 40: Western Europe, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 41: UK, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 42: UK, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 43: UK, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 44: Germany, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 45: Germany, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 46: Germany, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 47: France, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 48: France, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 49: France, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 50: Italy, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 51: Italy, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 52: Italy, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 53: Spain, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 54: Spain, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 55: Spain, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 56: Eastern Europe, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 57: Eastern Europe, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 58: Eastern Europe, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 59: Russia, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 60: Russia, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 61: Russia, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 62: North America, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 63: North America, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 64: North America, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 65: USA, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 66: USA, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 67: USA, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 68: Canada, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 69: Canada, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 70: Canada, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 71: South America, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 72: South America, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 73: South America, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 74: Brazil, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 75: Brazil, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 76: Brazil, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 77: Middle East, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 78: Middle East, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 79: Middle East, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 80: Africa, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 81: Africa, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 82: Africa, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 83: Pfizer Inc. Financial Performance

Table 84: Abbvie Inc. Financial Performance

Table 85: Novartis AG Financial Performance

Table 86: Ausio Pharmaceuticals LLC Financial Performance

Table 87: Teva Pharmaceutical Industries Ltd. Financial Performance

List Of Figures

Figure 1: Global Historic Market Growth, 2019-2024, $ Billion

Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Figure 3: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 4: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 5: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 6: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Antidepressants, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 7: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Fluoxetine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 8: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Paroxetine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 9: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Sertraline, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 10: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Hormone Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 11: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Anticonvulsant, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 12: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Phenytoin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 13: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Phenobarbital, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 14: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 15: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 16: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 17: Asia-Pacific, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 18: Asia-Pacific, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 19: Asia-Pacific, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 20: China, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 21: China, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 22: China, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 23: India, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 24: India, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 25: India, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 26: Japan, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 27: Japan, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 28: Japan, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 29: Australia, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 30: Australia, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 31: Australia, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 32: Indonesia, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 33: Indonesia, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 34: Indonesia, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 35: South Korea, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 36: South Korea, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 37: South Korea, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 38: Western Europe, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 39: Western Europe, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 40: Western Europe, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 41: UK, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 42: UK, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 43: UK, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 44: Germany, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 45: Germany, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 46: Germany, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 47: France, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 48: France, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 49: France, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 50: Italy, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 51: Italy, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 52: Italy, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 53: Spain, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 54: Spain, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 55: Spain, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 56: Eastern Europe, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 57: Eastern Europe, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 58: Eastern Europe, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 59: Russia, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 60: Russia, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 61: Russia, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 62: North America, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 63: North America, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 64: North America, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 65: USA, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 66: USA, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 67: USA, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 68: Canada, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 69: Canada, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 70: Canada, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 71: South America, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 72: South America, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 73: South America, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 74: Brazil, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 75: Brazil, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 76: Brazil, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 77: Middle East, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 78: Middle East, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 79: Middle East, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 80: Africa, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 81: Africa, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 82: Africa, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 83: Pfizer Inc. Financial Performance

Figure 84: Abbvie Inc. Financial Performance

Figure 85: Novartis AG Financial Performance

Figure 86: Ausio Pharmaceuticals LLC Financial Performance

Figure 87: Teva Pharmaceutical Industries Ltd. Financial Performance

Global Hospital-Acquired Infection Control Market 2022 – Market Opportunities And Strategies

What Is The Healthcare IT Consulting Market Overview In 2022?

How Will The Stem Cell Assay Market Grow In 2022?

Latest Single Use Bioprocessing Market Growth Study 2022-2026 By The Business Research Company

The Business Research Company offers the hospital acquired infection control market research report 2022 with industry size, share, segments and market growth

The Business Research Company offers the multiplex assays market research report 2022 with industry size, share, segments and market growth

The Business Research Company offers the healthcare it consulting market research report 2022 with industry size, share, segments and market growth

The Business Research Company offers the medical tourism market research report 2022 with industry size, share, segments and market growth

Postmenopausal Osteoporosis Treatment Global Market Report 2025 – By Drug Type (Bisphosphonates, Vitamin D3, Estrogen Agonist Or Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy, Other Drug Types), By Route Of Administration (Oral, Parenteral, Other Routes Of Administration), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels ) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Menopausal Hot Flashes Global Market Report 2025 – By Type (Hormonal Treatment, Non-hormonal Treatment, Alternative Treatment), By Pipeline Analysis (Phase III Drugs, Phase I and II Drugs), By Distribution Channel (Retail Pharmacies, Online Pharmacies, Hospital Pharmacies), By Application (51-55 Year Old Woman, 46-50 Year Old Woman, 40-45 Year Old Woman) – Market Size, Trends, And Global Forecast 2025-2034

View Report

PMS and Menstrual Health Supplements Global Market Report 2025 – By Products (Combined Nutritional Supplements, Single Nutritional Supplements), By Formulation (Softgels, Capsules/Tablets, Powder, Others Types), By Consumer Group (Perimenopause, Premenstrual Syndrome (PMS)), By Sales Channel (Direct Sales Channel, Online Sales Channel, Pharmacies/Drug Stores, Other Offline Channels) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Polycystic Ovarian Syndrome Treatment Global Market Report 2025 – By Drug Type (Oral Contraceptives, Ornithine Decarboxylase Inhibitors, Insulin-Sensitizing Agents, Anti-Depressants, Diuretics, Aromatase Inhibitors), By Surgery Type (Ovarian Wedge Resection, Laparoscopic Ovarian Drilling), By End User (Hospitals & Clinics, Ambulatory Surgical Centers, Diagnostic Centers, Gynecology Centers, Feminist Health Centers) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Artificial Intelligence in Diabetes Management Global Market Report 2025 – By Device (Diagnostic Devices, Glucose Monitoring Devices, Insulin Delivery Devices, Other Devices), By Techniques (Case-Based Reasoning, Intelligent Data Analysis), By End-Use (Hospitals, Clinics, Home Care Settings, Research Institutes) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Insulin Pens, Syringes, Pumps And Injectors Global Market Report 2025 – By Type (Pens, Injectors And Pumps, Syringes), By Pens (Reusable, Disposable), By Pumps (Tubed Pumps, Tubeless Pumps), By End Users (Hospitals, Homecare, Other End Users) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Insulin Drugs Global Market Report 2025 – By Product Type (Basal Or Long-Acting Insulins, Bolus Or Fast-Acting Insulins, Pre-Mixed, And Intermediate And Short Acting Insulins), By Source Type (Insulin Analogs, And Human Insulin), By Drug Classification (Branded Drugs, And Generic Drugs), By Application (Type 2 Diabetes, Type 1 Diabetes, And Gestational Diabetes), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, And Online) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Smart Insulin Pens Global Market Report 2025 – By Type (First Generation Pens, Second Generation Pens), By Usability (Prefilled, Reusable), By Application (Type 1 Diabetes, Type 2 Diabetes), By End User (Hospitals & Clinics, Ambulatory Surgical Centres, Home Care Settings) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Frequently Asked Questions

What is the definition of the Vasomotor Menopausal Symptoms (VMS) Treatment market?

How will the Vasomotor Menopausal Symptoms (VMS) Treatment market drivers and restraints affect the market dynamics? What forces will shape the Vasomotor Menopausal Symptoms (VMS) Treatment industry going forward?

The Vasomotor Menopausal Symptoms (VMS) Treatment market major growth driver - Menopausal Population Growth Fuels Expansion Of Vasomotor Menopausal Symptoms Treatment Market. For further insights on the Vasomotor Menopausal Symptoms (VMS) Treatment market request a sample here

What is the forecast market size or the forecast market value of the Vasomotor Menopausal Symptoms (VMS) Treatment market?

The Vasomotor Menopausal Symptoms (VMS) Treatment market size has grown strongly in recent years. The vasomotor menopausal symptoms (VMS) treatment market size has grown strongly in recent years. It will grow from $17.86 billion in 2024 to $19.19 billion in 2025 at a compound annual growth rate (CAGR) of 7.5%. The growth in the historic period can be attributed to hormone replacement therapy (hrt), menopause awareness, pharmaceutical developments, consumer demand. The vasomotor menopausal symptoms (VMS) treatment market size is expected to see strong growth in the next few years. It will grow to $24.81 billion in 2029 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to personalized medicine, non-hormonal innovations, nutritional and dietary interventions, telemedicine and digital health. Major trends in the forecast period include natural and alternative approaches, botanical and herbal remedies, menopause support groups, cognitive behavioral therapy (cbt). For further insights on the Vasomotor Menopausal Symptoms (VMS) Treatment market, request a sample here

How is the Vasomotor Menopausal Symptoms (VMS) Treatment market segmented?

The vasomotor menopausal symptoms (VMS) treatment market covered in this report is segmented –
1) By Drug Class: Antidepressants, Fluoxetine, Paroxetine, Sertraline, Hormone Therapy, Anticonvulsant, Phenytoin, Phenobarbital, Other Drug Classes
2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels
3) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-Users Subsegments:
1) By Antidepressants: SSRIs (Selective Serotonin Reuptake Inhibitors), SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors), TCAs (Tricyclic Antidepressants), MAOIs (Monoamine Oxidase Inhibitors), Atypical Antidepressants
2) By Fluoxetine: Depression, Obsessive-Compulsive Disorder (OCD), Panic Disorder, Generalized Anxiety Disorder (GAD), Post-Traumatic Stress Disorder (PTSD), Social Anxiety Disorder, Premenstrual Dysphoric Disorder (PMDD)
3) By Paroxetine: Depression, Obsessive-Compulsive Disorder (OCD), Panic Disorder, Generalized Anxiety Disorder (GAD), Post-Traumatic Stress Disorder (PTSD), Social Anxiety Disorder, Premenstrual Dysphoric Disorder (PMDD)
4) Sertraline: Depression, Obsessive-Compulsive Disorder (OCD), Panic Disorder, Post-Traumatic Stress Disorder (PTSD), Social Anxiety Disorder, Premenstrual Dysphoric Disorder (PMDD)
5) Hormone Therapy: Estrogen Replacement Therapy (ERT), Progestin Therapy, Combined Hormonal Therapy (CHT), Testosterone Replacement Therapy (TRT)
6) Anticonvulsant: Hydantoins, Barbiturates, Benzodiazepines, Valproates, Succinimides, Carboxylic Acid Derivatives
7) Phenytoin: Hydantoins
8) Phenobarbital: Barbiturates
9) Other Drug Classes: Antibiotics, Analgesics, Antidiabetics, Antihypertensives, Anticoagulants, Immunosuppressants, Antipsychotics, Antihistamines For further insights on the Vasomotor Menopausal Symptoms (VMS) Treatment market, request a sample here

Which region has the largest share of the Vasomotor Menopausal Symptoms (VMS) Treatment market? What are the other regions covered in the report?

North America was the largest region in the vasomotor menopausal symptoms (VMS) treatment market in 2024. The regions covered in vasomotor menopausal symptoms (VMS) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. For further insights on the Vasomotor Menopausal Symptoms (VMS) Treatment market, request a sample here.

Who are the major players in the Vasomotor Menopausal Symptoms (VMS) Treatment market?

Major companies operating in the vasomotor menopausal symptoms (vms) treatment market are Pfizer Inc., Abbvie Inc., Novartis AG, Ausio Pharmaceuticals LLC, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Kyowa Kirin Co. Ltd., Dr. Reddy's Laboratories Ltd., Alembic Pharmaceuticals Limited Inc., Apotex Inc., Hikma Pharmaceutical PLC, Endo Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Mundipharma International Ltd., Lupin Limited, Glenmark Pharmaceuticals Ltd., Hisamitsu Pharmaceutical Co. Inc., Zhejiang Huahai Pharmaceutical Co. Ltd., Emcure Pharmaceuticals Limited, Wockhardt Pvt. Ltd., QuatRx Pharmaceuticals Company, Bionovo Inc., Mithra Pharmaceuticals SA, EndoCeutics Inc., Zydus Group, Edgemont Pharmaceuticals LLC, MenoGeniX Inc., Agile Therapeutics Inc.. For further insights on the Vasomotor Menopausal Symptoms (VMS) Treatment market, request a sample here.

What are the key trends in the Vasomotor Menopausal Symptoms (VMS) Treatment market?

Major trends in the Vasomotor Menopausal Symptoms (VMS) Treatment market include Increasing The Emphasis On Drug Approvals To Provide Better Treatment Options. For further insights on the Vasomotor Menopausal Symptoms (VMS) Treatment market, request a sample here.

What are the major opportunities in the Vasomotor Menopausal Symptoms (VMS) Treatment market? What are the strategies for the Vasomotor Menopausal Symptoms (VMS) Treatment market?

For detailed insights on the major opportunities and strategies in the Vasomotor Menopausal Symptoms (VMS) Treatment market, request a sample here.

How does the Vasomotor Menopausal Symptoms (VMS) Treatment market relate to the overall economy and other similar markets?

For detailed insights on Vasomotor Menopausal Symptoms (VMS) Treatment's relation to the overall economy and other similar markets, request a sample here.

What are the latest mergers and acquisitions in the Vasomotor Menopausal Symptoms (VMS) Treatment industry?

For detailed insights on the mergers and acquisitions in the Vasomotor Menopausal Symptoms (VMS) Treatment industry, request a sample here.

What are the key dynamics influencing the Vasomotor Menopausal Symptoms (VMS) Treatment market growth? SWOT analysis of the Vasomotor Menopausal Symptoms (VMS) Treatment market.

For detailed insights on the key dynamics influencing the Vasomotor Menopausal Symptoms (VMS) Treatment market growth and SWOT analysis of the Vasomotor Menopausal Symptoms (VMS) Treatment industry, request a sample here.